Results 121 to 130 of about 28,404 (198)

Correction to: The Potential Role of Peer Support Workers in General Practice: Perspectives of Consumers, Carers, Peer Support Workers and General Practice Staff. [PDF]

Adm Policy Ment Health
Lawn S, Rattray M, Fuss B, Shelby-James T, Byrne L, Worley P, Manger S, Harris G, Gye B, Alvarez A, Henkel D, Creedon P, Stevenson T, Isaac V, Kaambwa B, Ullah S, Phegan C.   +16 more
europepmc   +1 more source

Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms. [PDF]

Drugs
Young Moss S, Lee A, Simon JA.
europepmc   +1 more source

Assessment of Biophilic Design in Educational Corridors and Stairwells Using fNIRS and GSR with Generative AI Stimuli. [PDF]

Sensors (Basel)
Kim JY, Park SJ.
europepmc   +1 more source

Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting. [PDF]

Menopause
Hsu CD, Carpenter RM, Richardson G, Guo F, Adekanmbi V, Hoang TN, Berenson AB.   +6 more
europepmc   +1 more source

Can DNN models simulate appearance variations of #TheDress? [PDF]

Iperception
Kuriki I, Saito H, Okubo R, Kiyokawa H, Shinozaki T.   +4 more
europepmc   +1 more source

Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause. [PDF]

Health Qual Life Outcomes, 2023
Schultz NM, Morga A, Siddiqui E, Rhoten SE.   +3 more
europepmc   +1 more source

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials. [PDF]

Proc (Bayl Univ Med Cent)
AlBarakat MM, Feras AlSamhori J, Abdelaziz A, Elrosasy A, Elzeftawy MA, Ahmed Youssef R, Altawalbeh RB, Abuelazm M, Abdelazeem B.   +8 more
europepmc   +1 more source

The Structural Types of the Polarization Detection Unit in Imaging Polarimeter Based on the Stokes Parameter Method. [PDF]

Sensors (Basel)
Li Y, Guo X, Zhang K, Li X, Kong F, Jia Z.   +5 more
europepmc   +1 more source

Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. [PDF]

Adv Ther
Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, Ottery FD.   +6 more
europepmc   +1 more source

FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option. [PDF]

Ann Med Surg (Lond)
Elendu C, Okahia TW, Blewusi GS, Meduoye OOM, Ogelle EC, Egbo AR, Nwankwo VC, Amaefule KC, Emechebe SL, Mohamed AA, Ogedengbe OS, Aggreh OP, Obi DI, Orji VI, Bakare SO, Adediran FD, Adetoye F, Akande BA, Ogunsola OC, Olanlege AM.   +19 more
europepmc   +1 more source